Search results
Ionis, Biogen Down on Ending Development of ALS Drug - Biogen (NASDAQ:BIIB), Heron Therapeutics...
Benzinga· 3 days agoShares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market...
Biogen, Ionis to discontinue development of experimental ALS drug
Reuters via Yahoo News· 5 days agoShares of Biogen and Ionis were each down nearly 2% in premarket trading. This marks another setback...
Biogen, Ionis shelve ALS drug following study failure
BioPharma Dive via Yahoo Finance· 5 days agoWhile results indicated the drug works as intended, it didn’t have enough of an effect on a protein...
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Zacks via Yahoo Finance· 5 days agoBiogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA...
Biogen and Ionis halt ALS drug development after trial setback By Investing.com
Investing.com· 5 days agoBiogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) have announced the...
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic...
Morningstar· 5 days agoIonis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense ...
Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data
FierceBiotech· 5 days agoBiogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the...
Biogen Stock Continues Its 24% Sprint On A Twist In Alzheimer's Treatment
Investor's Business Daily· 5 days agoBiogen stock jumped early Wednesday after the Food and Drug Administration gave its Eisai-partnered...
Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis
Market Watch· 5 days agoIonis Pharmaceuticals and Biogen have canned development of an investigational therapy for amyotrophic lateral sclerosis after testing showed it didn't slow the disease process ...
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
Market Watch· 4 days agoIt also did not show an impact on clinical outcome measures relating to function, breathing and...